Search Results - "Subbiah V"

ROME trial wasn't built in a day: the decade-long journey to randomized evidence in precision oncology.

Authors: Subbiah, V.¹ (AUTHOR) viveksubbiah@outlook.com

Source: Annals of Oncology. Apr2026, Vol. 37 Issue 4, p575-577. 3p.

SVC BASED ENCRYPTION METHOD FOR PRIVACY PROTECTION IN SURVEILANCE VIDEO.

Authors: raj, T. Sugirtha Subbiah, V. sankar, P. Aathi et al.

Source: Turkish Online Journal of Qualitative Inquiry. 2021, Vol. 12 Issue 10, p4309-4321. 13p.

Subject Terms: Video surveillance, Video compression, Cellular automata, Videos, Privacy

The best management for most patients with incurable cancer is on a clinical trial.

Authors: Subbiah, V. Kurzrock, R.

Source: Annals of Oncology. Mar2025, Vol. 36 Issue 3, p240-243. 4p.

This result is not displayed to guests.
Login for full access.

Unlocking precision oncology with FGFR inhibition in urothelial carcinoma.

Authors: Sonpavde, G.P. Subbiah, V.

Source: Annals of Oncology. Feb2024, Vol. 35 Issue 2, p150-153. 4p.

1028eTiP DiscovHER PAN-206: Phase II tumour-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2 (HER2)-overexpressing solid tumours.

Authors: Subbiah, V. Makker, V. Oh, D-Y. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS667-S668. 2p.

998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation.

Authors: Subbiah, V. Bashir, B. El-Khoueiry, A.B. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS652-S653. 2p.

Translating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs!

Authors: Subbiah, V. Pant, S.

Source: Annals of Oncology. Jun2023, Vol. 34 Issue 6, p503-506. 4p.

Implementation of Field Oriented Speed Sensorless Control of Induction Motor Drive.

Authors: Gunabalan, R. Subbiah, V.

Source: International Journal on Electrical Engineering & Informatics. Dec2016, Vol. 8 Issue 4, p727-738. 12p.

Cancer: slaying the nine-headed Hydra.

Authors: Adashek, J.J. Subbiah, V. Westphalen, C.B. et al.

Source: Annals of Oncology. Jan2023, Vol. 34 Issue 1, p61-69. 9p.

Single Inverter Fed Speed Sensorless Vector Control of Parallel Connected Two Motor Drive.

Authors: Gunabalan, R. Subbiah, V.

Source: Automatika: Journal for Control, Measurement, Electronics, Computing & Communications; 2016, Vol. 57 Issue 2, p416-427, 12p

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.

Authors: Subbiah, V. Iannotti, N.O. Gutierrez, M. et al.

Source: Annals of Oncology. May2022, Vol. 33 Issue 5, p522-533. 12p.

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.

Authors: Subbiah, V. Kreitman, R.J. Wainberg, Z.A. et al.

Source: Annals of Oncology. Apr2022, Vol. 33 Issue 4, p406-415. 10p.

Right to Try, expanded access use, Project Facilitate, and clinical trial reform.

Authors: Reddy, N.K. Subbiah, V.

Source: Annals of Oncology. Sep2021, Vol. 32 Issue 9, p1083-1086. 4p.

Static Var Compensators & Power System Stabilizers with Adaptive Neuro Fuzzy Controllers in Wind Farms.

Authors: Manju, P. Subbiah, V.

Source: International Review on Modelling & Simulations. Apr2013, Vol. 6 Issue 2, p473-479. 7p. 9 Diagrams, 4 Graphs.

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Authors: Subbiah, V. Shen, T. Terzyan, S.S. et al.

Source: Annals of Oncology. Feb2021, Vol. 32 Issue 2, p261-268. 8p.

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.

Authors: Subbiah, V. Solit, D.B. Chan, T.A. et al.

Source: Annals of Oncology. Sep2020, Vol. 31 Issue 9, p1115-1118. 4p.

Precision oncology for biliary tract tumors: it's written in blood!

Authors: Gouda, M.A. Subbiah, V.

Source: Annals of Oncology. Dec2022, Vol. 33 Issue 12, p1209-1211. 3p.

This result is not displayed to guests.
Login for full access.

Selective RET kinase inhibition for patients with RET-altered cancers.

Authors: Subbiah, V Velcheti, V Tuch, B B et al.

Source: Annals of Oncology. Aug2018, Vol. 29 Issue 8, p1869-1876. 8p. 1 Color Photograph, 2 Graphs.